PR 600 companion diagnostic - Merck & Co
Alternative Names: PR600 companion diagnostic - Merck & CoLatest Information Update: 28 Nov 2023
At a glance
- Originator Prometheus Biosciences
- Developer Merck & Co
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Inflammatory-bowel-diseases(Diagnosis) in USA
- 16 Jun 2023 Prometheus Biosciences has been acquired and merged into Merck & Co
- 03 Jan 2022 Prometheus Biosciences receives final milestone payments from Dr. Falk Pharma for development of PR 600 and PR 600 companion diagnostic